Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes.
作者信息
d'Alessandro Miriana, Cameli Paolo, Bergantini Laura, Franchi Federico, Scolletta Sabino, Bargagli Elena
机构信息
Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences and Neurosciences, Siena University Hospital, Siena, Italy.
Department of Medicine, Surgery and Neuroscience, Anesthesia and Intensive Care Unit, University of Siena, Siena, Italy.
出版信息
J Med Virol. 2021 Feb;93(2):657. doi: 10.1002/jmv.26431. Epub 2020 Aug 25.
Abstract
摘要
相似文献
1
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes.
J Med Virol. 2021 Feb;93(2):657. doi: 10.1002/jmv.26431. Epub 2020 Aug 25.
2
Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019.
Respir Investig. 2021 Sep;59(5):596-601. doi: 10.1016/j.resinv.2021.04.002. Epub 2021 Apr 27.
3
Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China.
Biosci Trends. 2020 Sep 21;14(4):290-296. doi: 10.5582/bst.2020.03197. Epub 2020 Jun 21.
4
Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients.
Int J Biol Sci. 2021 Apr 10;17(6):1565-1573. doi: 10.7150/ijbs.58825. eCollection 2021.
5
Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.
Iran Biomed J. 2021 Nov 1;25(6):381-9. doi: 10.52547/ibj.25.6.381.
6
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.
Int J Environ Res Public Health. 2022 Feb 15;19(4):2176. doi: 10.3390/ijerph19042176.
7
Krebs von den Lungen-6 levels at admission predicts exercise-induced hypoxemia before and after discharge in patients with COVID-19.
Respir Investig. 2024 May;62(3):369-374. doi: 10.1016/j.resinv.2024.02.011. Epub 2024 Mar 1.
8
Plasma Krebs von den Lungen glycoprotein, lung injury, and noninvasive ventilation in Duchenne muscular dystrophy.
Am J Phys Med Rehabil. 2012 Oct;91(10):831-5. doi: 10.1097/PHM.0b013e31825f1414.
9
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
BMC Pulm Med. 2017 Nov 17;17(1):144. doi: 10.1186/s12890-017-0489-0.
10
Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Rheumatol Int. 2018 May;38(5):813-819. doi: 10.1007/s00296-018-3987-3. Epub 2018 Feb 17.
引用本文的文献
1
Eight-fold increased COVID-19 mortality in autosomal dominant tubulointerstitial kidney disease due to MUC1 mutations: an observational study.
BMC Nephrol. 2024 Dec 18;25(1):449. doi: 10.1186/s12882-024-03896-1.
2
Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance.
J Inflamm (Lond). 2023 Mar 20;20(1):11. doi: 10.1186/s12950-023-00333-2.
3
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.
Int J Environ Res Public Health. 2022 Feb 15;19(4):2176. doi: 10.3390/ijerph19042176.
4
Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
Virology. 2022 Jan;566:106-113. doi: 10.1016/j.virol.2021.11.006. Epub 2021 Dec 4.
5
Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019.
Clin Chim Acta. 2021 Jun;517:48-53. doi: 10.1016/j.cca.2021.02.012. Epub 2021 Feb 22.
6
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy.
Cancers (Basel). 2021 Feb 9;13(4):689. doi: 10.3390/cancers13040689.
7
Prognostic bioindicators in severe COVID-19 patients.
Cytokine. 2021 May;141:155455. doi: 10.1016/j.cyto.2021.155455. Epub 2021 Jan 28.
8
Serial KL-6 measurements in COVID-19 patients.
Intern Emerg Med. 2021 Sep;16(6):1541-1545. doi: 10.1007/s11739-020-02614-7. Epub 2021 Jan 16.
9
Peripheral biomarkers' panel for severe COVID-19 patients.
J Med Virol. 2021 Mar;93(3):1230-1232. doi: 10.1002/jmv.26577. Epub 2020 Oct 10.
本文引用的文献
1
Serum KL-6 can distinguish between different phenotypes of severe COVID-19.
J Med Virol. 2021 Jan;93(1):158-160. doi: 10.1002/jmv.26268. Epub 2020 Jul 19.
2
Serum KL-6 concentrations as a novel biomarker of severe COVID-19.
J Med Virol. 2020 Oct;92(10):2216-2220. doi: 10.1002/jmv.26087. Epub 2020 Jun 9.
3
Nationwide system to centralize decisions around ECMO use for severe COVID-19 pneumonia in Japan (Special Correspondence).
J Intensive Care. 2020 Apr 24;8:29. doi: 10.1186/s40560-020-00445-4. eCollection 2020.
4
Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
Arthritis Res Ther. 2019 Feb 14;21(1):58. doi: 10.1186/s13075-019-1835-9.
Zotero 插件